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Monocyte-Derived Dendritic cells 
are essential for cD8+ T cell 
activation and antitumor responses 
after local immunotherapy
Sabine Kuhn† , Jianping Yang and Franca Ronchese*
Malaghan Institute of Medical Research, Wellington, New Zealand
Tumors harbor several populations of dendritic cells (DCs) with the ability to prime 
tumor-specific T cells. However, these T cells mostly fail to differentiate into armed 
effectors and are unable to control tumor growth. We have previously shown that 
treatment with immunostimulatory agents at the tumor site can activate antitu-
mor immune responses and is associated with the appearance of a population 
of monocyte-derived DCs (moDCs) in the tumor and tumor-draining lymph node 
(dLN). Here, we use depletion of DCs or monocytes and monocyte transfer to show 
that these moDCs are critical to the activation of antitumor immune responses. 
Treatment with the immunostimulatory agents monosodium urate crystals and 
Mycobacterium smegmatis induced the accumulation of monocytes in the dLN, 
their upregulation of CD11c and MHCII, and expression of iNOS, TNFα, and 
IL12p40. Blocking monocyte entry into the lymph node and tumor through neutral-
ization of the chemokine CCL2 or inhibition of colony-stimulating factor-1 receptor 
signaling prevented the generation of moDCs, the infiltration of tumor-specific T 
cells into the tumor, and antitumor responses. In a reciprocal fashion, monocytes 
transferred into mice depleted of CD11c+ cells were sufficient to rescue CD8+ T cell 
priming in lymph node and delay tumor growth. Thus, monocytes exposed to the 
appropriate conditions become powerful activators of tumor-specific CD8+ T cells 
and antitumor immunity.
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inTrODUcTiOn
Dendritic cells (DCs) are critical for the induction of adaptive immune responses. DCs in tumors 
and tumor-draining lymph nodes (dLNs) are often loaded with tumor material and are able to induce 
proliferation of tumor-specific T cells in the dLN (1–3). Although presentation of tumor antigen 
by specific DC subsets is necessary for tumor regression in patients and mouse models (4, 5), it 
Abbreviations: BM, bone marrow; CSF1, colony-stimulating factor-1; CSF1R, CSF1 receptor; DAPI, 6′-diamidino-2-phe-
nylindole; DC, dendritic cell; dLN, draining LN; DT, diphtheria toxin; moDC, monocyte-derived DC; Msmeg, Mycobacterium 
smegmatis; MSU, monosodium urate; MDSC, myeloid-derived suppressor cell; NK, natural killer; OVA, ovalbumin; ROS, 
reactive oxygen species; WT, wild type.
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is mostly insufficient: proliferating T cells remain in the LN, fail 
to differentiate into fully armed effector cells, and are unable to 
infiltrate the tumor and mediate tumor rejection (3).
Several studies have shown that immunostimulating treat-
ments that activate DCs also lead to induction of powerful CD8+ 
T effector cells that eliminate tumor cells and delay tumor growth 
(6–10). Unexpectedly, by carrying out a detailed study of the 
effects of these treatments on DC phenotype, we found that suc-
cessful therapies do not simply activate existing DC subsets, but 
they also elicit the differentiation of monocytes into monocyte-
derived DCs (moDCs) in the dLNs (9, 11, 12). Whether moDCs 
are simply passengers in the induced inflammatory response or 
powerful antigen-presenting cells that are especially suited to 
stimulating potent antitumor immunity remains unclear.
Most of our knowledge of moDCs comes from infection 
models. Under inflammatory conditions, moDCs can become a 
substantial population that complements the range of steady state 
DCs (13–15). MoDCs upregulate CD11c and MHCII but gener-
ally retain expression of monocyte markers such as Ly6C, Ly6B, 
CD64, and FcϵRIα (15–17). They can mediate effector functions 
via their production of the Th1 cytokines TNFα and IL-12 as well 
as through direct cytotoxicity via NO production (13, 15, 17, 18). 
Importantly, moDCs can also prime Th1 immunity and cytotoxic 
T cell responses (14, 15, 19), recognized components of successful 
antitumor responses (4, 20, 21).
In a tumor context, the role of monocytes as precursors of 
immunostimulatory moDCs is rarely considered. Instead, Ly6Chi 
CCR2+ monocytes are known to give rise to the majority of 
tumor-associated macrophages (22–24) and contribute to the 
pool of monocytic myeloid-derived suppressor cells (MDSCs) 
that promote tumor growth and suppress antitumor immunity 
(25, 26). Nonetheless, experiments in mouse models show that 
monocytes can also differentiate into inflammatory DCs that 
produce reactive oxygen species (ROS) and directly mediate anti-
tumor responses independently of effector T cells (27). Similarly, 
in human skin lesions treated with toll-like receptor 7/8 agonists, 
inflammatory DCs acquire expression of cytotoxic mediators 
in vivo and become directly tumoricidal in vitro (28).
In addition to acquiring direct tumoricidal function, moDCs 
can also serve as antigen-presenting cells in the tumor context. 
In a recent study, anthracyclin chemotherapy induced Ly6Chi 
CD11c+ cells at the tumor site by an ATP- and CCR2/CCL2-
dependent mechanism (29, 30). These cells, but not PDCA+ 
pDCs or BATF3-dependent DCs, could activate T cells in  situ 
and were necessary for antitumor activity (29). Interestingly, 
lymph nodes or tertiary lymphoid tissues were not necessary for 
this response, suggesting that it might rely on existing memory 
T cells rather than de novo priming of naive T cells. It remains 
to be determined whether the key role of moDCs is specific to 
chemotherapy, or whether it may extend to antitumor immune 
responses induced by other treatments. In this respect, it is note-
worthy that work from our group indicates that moDCs can also 
be elicited by peritumoral treatment with the toll-like receptor 3 
ligand polyI:C, or the immunostimulatory agents monosodium 
urate (MSU) crystals and Mycobacterium smegmatis (Msmeg). 
Importantly, we find that the presence of moDCs correlates with 
CD8+ T cell activation and treatment success in several tumor 
models (9, 12). Whereas moDCs are frequently observed after 
exposure to infectious stimuli, the precise conditions leading to 
their generation have not been determined. In our model, polyI:C 
and MSU +  Msmeg both induced elevated levels of IFNγ and 
IL-12p70 in serum (9). These cytokines were reported to play a 
key role in moDC generation and function (18). In addition, we 
observed that MSU + Msmeg induced the release of IL-1β, which 
was required for the antitumor response (11).
In this paper, we sought to determine the relevance of moDCs 
in antitumor immunity. We used a model of murine melanoma 
and local treatment with MSU + Msmeg to show that moDCs are 
critical for treatment success. MSU + Msmeg induced recruitment 
of monocytes from blood and their differentiation into inflamma-
tory moDCs in the dLN. Treatment with a colony-stimulating 
factor-1 receptor (CSF1R) inhibitor similar to the ones currently 
in clinical trial to block MDSCs also blocked monocyte and 
moDC accumulation in the dLN, as well as tumor-specific T cell 
proliferation in dLN and antitumor activity. Finally, adoptively 
transferred monocytes were able to differentiate into CD11c+ 
moDCs in  vivo and were sufficient to restore MSU +  Msmeg 
antitumor responses in CD11c-depleted animals. Taken together, 
these results indicate that moDCs are critical for the success of 
MSU + Msmeg immunotherapy and suggest a common mecha-
nism by which immunotherapy and chemotherapy may be able to 
transform tumors into sites of immune activation.
MaTerials anD MeThODs
Mice
All mice were bred at the Malaghan Institute of Medical 
Research Biomedical Research Unit. C57BL/6J (CD45.2+), 
B6.SJL-Ptrprca (CD45.1+), and CD11c-DTR mice were origi-
nally from Jackson Laboratories, USA; OTI mice expressing a 
transgenic TCR specific for Kb + ovalbumin (OVA)257–264 were 
from Melbourne University, Australia. CD11c-DTR bone mar-
row (BM) chimeras were generated as described (9) by irradiat-
ing (2 × 550 rad) C57BL/6J hosts followed by i.v. transfer of 107 
CD11c-DTR BM cells. Chimeras were rested for at least 8 weeks 
before being used in experiment. All experimental procedures 
were approved by the Victoria University of Wellington Animal 
Ethics Committee.
Tumor cell lines and Tumor challenge
The B16-F1 murine melanoma (American Type Culture 
Collection, ATCC) and the B16.OVA melanoma expressing a 
truncated OVA protein (31) were maintained in complete Iscove’s 
modified Dulbecco’s medium as described (1), and extended 
in vitro passaging was avoided. For tumor challenge, cells were 
washed 3× in medium, and 105 tumor cells were injected s.c. 
into the flank of mice. Tumor size and survival were calculated 
as described (1).
MsU + Msmeg Treatment
Mice were treated with 2  ×  106 colony-forming units (CFU) 
of Msmeg (mc2155) and 250  μg MSU crystals (containing 
<0.01 EU/10 mg) in a total volume of 100 μl PBS as described 
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(9). Full treatment involved four injections of MSU +  Msmeg 
given s.c. around the tumor, starting when the tumor became 
palpable (usually around days 7–9) and repeated every second 
day thereafter. Control mice received 100 μl PBS (Invitrogen).
Flow cytometry
Lymph nodes or tumors were digested using DNase I and 
Liberase TL (Roche) as described (9). Blood was collected in 
Alsever’s solution, and red blood cells were lysed in ammonium-
chloride-tris buffer (both made in house). Single cell suspen-
sions were then resuspended in FACS buffer (PBS with 10 mM 
EDTA, Sigma; 2% FBS, Gibco; and 0.01% NaN3, Sigma) and 
blocked with anti-mouse CD16/32 (2.4G2) before staining with 
fluorescent antibodies specific for the following markers: CD45 
(30F11), CD45.1 (A20), CD4 (GK1.5), CD8α (53-6.7), CD11c 
(HL3), CD11b (M1/70), Vα2 (B20.1), and Vβ5.1/5.2 (MR9-4), 
all from BD Biosciences; Ly6C (HK1.4), CD64 (X54-5/7.1), 
CD135 (A2F10), and MHCII (M5/114.15.2) from Biolegend; 
CD115 (AFS98), CD45.2 (104), and Ly6G (1A8) from eBiosci-
ence; Ly6B (7/4) from AbD Serotec; and CCR2 (475301) from 
R&D Systems. Anti-CD4 (GK1.5), -CD8α (2.43), and -MHCII 
(3JP) were affinity purified from hybridoma supernatants. 
Streptavidin-PE, -APC, or PE-Texas-Red (BD Biosciences) were 
used where required. Dead cells were excluded by staining with 
6′-diamidino-2-phenylindole (DAPI) or Live/Dead Fixable blue 
(Invitrogen). For intracellular cytokine staining, cell suspensions 
were incubated for 6 h in 1 μg/ml Golgi Stop (BD Biosciences) 
and 2 μg/ml Brefeldin A (eBioscience) with no restimulation. 
After surface staining, cells were stained with anti-IL-12p40 
(C17.8 from eBiosciences), anti-TNF-α (MP6-XT22, from 
BD Biosciences) antibodies, or isotype controls (R3-34 BD 
Biosciences or EBRG1, eBioscience), using the BD Cytofix/
Cytoperm kit (BD Biosciences). Staining for iNOS was done 
in the same way with M-19 polyclonal antibody (sc-650, Santa 
Cruz Biotechnology) or control rabbit IgG (sc-2027, Santa 
Cruz Biotechnology) but without incubation with Golgi Stop/
Brefeldin A. Acquisition was performed on a BD LSRII SORP 
or a BD LSR Fortessa SORP (Becton Dickinson), and data were 
analyzed using FlowJo Version 9.8.3 (Tree Star).
Dc Depletion
For DC depletion, CD11c-DTR BM chimeras were injected i.p. 
with 15  ng diphtheria toxin (DT) (Sigma-Aldrich) per gram 
body weight 12  h prior to each MSU +  Msmeg treatment. In 
some experiments, depletion was confirmed by flow cytometry 
of tumor-draining LNs and tumors as shown in Figure S1 in 
Supplementary Material.
In vivo T cell Proliferation
CD8+ T cells from spleens and LNs of OTI × B6.SJL-Ptprca mice 
were positively selected using anti-CD8+ MACS Beads (Miltenyi 
Biotec) and labeled with CFSE as described (32). Purity was >87% 
as assessed by positive staining with anti-CD8α, -Vα2, and -Vβ5 
antibodies. About 2 × 106 cells were injected i.v. into C57BL/6J 
or CD11c-DTR BM chimeric hosts bearing established B16.OVA 
tumors. OTI proliferation was assessed in tumor-draining LNs 
6 days later.
inhibition of csF1 signaling
The small-molecule GW2580, a selective inhibitor of the CSF1 
receptor kinase (33), was used to block CSF1 signaling in vivo. 
Tumor-bearing mice received six daily doses of either 160 mg/
kg GW2580 (kindly provided by Prof Peter Shepherd, University 
of Auckland, New Zealand) in a solution of 0.5% methylcellulose 
(Sigma) and 0.1% Tween80 (Sigma) in dH2O, or control diluent, 
by oral gavage starting 4 h before the first MSU + Msmeg treat-
ment. This dose was previously shown to achieve 100% inhibition 
of CSF1-dependent monocyte growth (33).
Monocyte isolation from BM and adoptive 
Transfer
Monocytes were enriched from BM as described (15, 34) with 
minor modifications. BM cell suspensions were incubated with 
biotinylated antibodies specific for the following markers: B220 
(RA3-6B2), CD19 (1D3), CD49b (DX5), CD90.2 (53-2.1), and 
Ly-76 (Ter119) (all from eBioscience); Ly6G (1A8) and CD135 
(A2F10) (from Biolegend); and CD11c (HL3) and CD24 (M1/69) 
(from BD Biosciences), followed by incubation with anti-Biotin 
MACS beads (1  μl/106 cells) and magnetic separation on an 
Automacs (Miltenyi Biotec). The enriched population contained 
85–91% Ly6Chigh monocytes, the majority of which also expressed 
CD11b, Ly6B, CD64, CCR2, and CD115 (CSF1R). Recipients 
received 1–2 × 106 enriched monocytes i.v.
ccl2 Blocking
Mice bearing palpable B16.OVA tumors were injected i.p. with 
100 μg anti-CCL2 antibody (clone 2H5, Biolegend) or Armenian 
hamster IgG control antibody (clone HTK888, Biolegend) 2  h 
prior to i.v. transfer of purified BM monocytes.
statistical analyses
Statistical analyses were done using GraphPad Prism 5. Two-tailed 
Student’s t-test was used to compare two groups. Multiple groups 
were compared by one-way ANOVA with Tukey’s post-test, or 
Kruskal-Wallis test with Dunn’s post-test for data that were not 
normally distributed. Survival was analyzed using the log-rank 
test with Bonferroni’s correction for multiple testing. Differences 
of p < 0.05 were deemed significant (*), p < 0.01 very significant 
(**), and p < 0.001 extremely significant (***).
resUlTs
Dcs are required for Tumor 
immunotherapy by MsU + Msmeg
Treatment of established B16 melanomas with the immune-
activating agents MSU  +  Msmeg delays tumor growth and 
increases survival (9, 11). Treatment success requires adaptive 
immunity, in particular CD8+ T cells, and correlates with the 
accumulation of moDCs in dLN as early as 1 day after the first 
MSU + Msmeg treatment (9). To test whether DCs are required 
for MSU + Msmeg immunotherapy, we used CD11c-DTR BM 
chimeras and depleted them of CD11c+ cells by administration 
of DT throughout the duration of MSU +  Msmeg treatment. 
Depletion of CD11c+ cells abrogated the treatment-induced 
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reduction in tumor size and increase in survival (Figures 1A,B). 
Successful depletion of CD11c+MHCII+ DCs in dLN after the 
last treatment was verified in separate experiments (Figure 1C) 
and confirmed that different DCs subsets, including CD8α+ DCs, 
CD11b+ DCs, CD8α−CD11b− DCs, and CD11b+CD64+Ly6C+ 
moDCs, were all significantly reduced in DT-treated CD11c-DTR 
chimeras (Figure  1D; Figure S1 in Supplementary Material). 
Thus, CD11c+ DCs are necessary for MSU + Msmeg antitumor 
activity.
MsU + Msmeg recruits Monocytes from 
Blood to dln and induces expression of 
Dc Markers
We sought to establish the origin of the moDCs induced by 
MSU + Msmeg treatment. A substantial population of moDCs was 
FigUre 1 | Dendritic cells are required for the activation of antitumor immunity by MsU + Msmeg. C57BL/6 WT (C57WT) or CD11c-DTR BM chimeras 
were injected with B16 melanoma tumors, treated every second day for four times with MSU + Msmeg or PBS, and at the same time depleted of CD11c+ cells by 
i.p. DT treatment as indicated. (a) Individual tumor sizes in each group, as measured on the day when average tumor size in the C57 WT control group approached 
150 mm2 (days 17–23 after tumor challenge). Horizontal lines show mean ± SEM. (B) Survival of tumor challenged mice. Data in (a,B) are pooled from two 
independent experiments each with 3–5 mice/group. (c) Numbers of total DCs (CD11c+MHCII+) and (D) numbers of moDCs (CD11c+MHCII+CD11b+CD64+Ly6C+) 
in draining and contralateral LNs 2 days after the completion of MSU + Msmeg treatment. Data refer to one of two independent experiments that gave similar 
results. Graphs show mean + SEM for 5 mice/group. Statistical analysis in (a,c,D) was by one-way ANOVA with Tukey’s post-test. (B) Log-rank test with 
Bonferroni’s correction for multiple testing.
observed in the dLN of intact mice that received MSU + Msmeg 
subcutaneously. MoDCs formed a distinct population within 
the CD11c+MHCII+ DCs, uniformly expressing high levels of 
CD11b, Ly6C, Ly6B, and CD64 (Figure  2A). The numbers of 
moDCs and monocytes in dLN were comparable to the numbers 
seen in similarly treated tumor-bearing animals [Figure 2B (9)] 
and represented about 10% of the total DC population in treated 
dLNs. In contrast, the proportions of other DC subsets were not 
significantly affected by MSU + Msmeg treatment (9).
We then examined the fate of purified BM monocytes trans-
ferred into the blood of recipient mice. Transferred cells were 
recruited to MSU +  Msmeg-treated dLN (Figures  2C,D), and 
by 17  h after transfer they had already upregulated expression 
of the DC markers CD11c and MHCII (Figure  2E). Thus, the 
early influx of moDCs into the dLN of MSU + Msmeg-treated 
mice is likely due to monocytes entering the dLN directly from 
FigUre 2 | Monocyte accumulation and upregulation of Dcs markers in the dln of MsU + Msmeg-treated mice. (a,B) Mice were injected s.c. with 
MSU + Msmeg or PBS on days 0 and 2. About 17 h later dLNs were harvested and analyzed by flow cytometry. (a) Expression of DC and monocyte lineage 
markers on total DCs (MHCII+CD11c+), CD11b+ DC (CD11b+CD8−Ly6B−Ly6C− DCs), CD8a+ DC (CD8a+CD11b− DCs), and moDCs (CD11b+Ly6B+Ly6C+ DCs). 
(B) Frequency and number of moDCs (CD11b+Ly6B+Ly6C+CD11c+MHCII+) and monocytes (CD11b+Ly6B+Ly6C+CD11c−) in dLN. Data are pooled from two 
independent experiments each with 3–5 mice/group. (c,D,e) As in (a) but mice received two million CD45.1+ BM monocytes i.v. 17 h before analysis. 
(c) Identification of transferred monocytes in dLN. (D) Number of transferred monocytes and (e) expression of CD11c and MHCII on transferred monocytes, 
expressed as median fluorescence intensity (MFI). Data in (c–e) are from one of two independent experiments, each with 3–5 mice/group, that gave similar results. 
All graphs show mean + SEM. Statistical analyses used a Student’s t-test.
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the blood, rather than monocytes migrating from the tumor to 
the dLN. However, these data do not rule out that, at later time 
points, moDCs in dLN may originate from either tumor or blood.
ccr2+ Monocytes enter dln and Tumors 
in a ccl2-Dependent Manner
Blood monocytes can be divided into two subsets: Ly6Clow 
patrolling monocytes that migrate in and out of tissues in the 
steady state, and Ly6Chigh inflammatory monocytes that express 
CCR2 and are actively recruited to sites of inflammation (35). 
We therefore examined CCR2 expression on monocytes, moDCs, 
and cDCs in the dLN of mice treated with MSU  +  Msmeg 
45  h earlier. Monocytes and moDCs both expressed CCR2, 
while other Ly6B−Ly6C− DCs were mostly CCR2 negative 
(Figure 3A). Consistent with this observation, the frequency of 
blood monocytes expressing CCR2+ was diminished 15 h after 
MSU + Msmeg treatment, suggesting recruitment into inflamed 
tissues (Figure 3B).
We also investigated the role of CCL2 in the recruitment of 
monocytes to the dLN. CCL2, also known as MCP-1, is the main 
ligand of CCR2, but its role in the migration of monocytes to 
sites of inflammation is controversial (19, 36). Systemic treatment 
with CCL2-blocking antibodies almost completely inhibited the 
recruitment of both i.v. transferred BM monocytes and host 
monocytes to the dLN (Figure 3C). The proportions of transferred 
and host monocytes in tumors were also significantly reduced in 
anti-CCL2-treated mice (Figure 3D). The effects of CCL2 block-
ade on tumor progression were not determined. Thus, CCR2+ 
monocytes enter the dLN and tumors of MSU + Msmeg-treated 
mice in a CCL2-dependent manner.
Blocking Monocyte and moDc 
recruitment abolishes MsU + Msmeg-
induced antitumor activity
To begin to address the contribution of moDCs to the antitumor 
immune response induced by MSU + Msmeg, we used treatment 
with GW2580, a small-molecule inhibitor highly specific for the 
CSF1R kinase (33). CSF1 promotes proliferation, survival, and 
differentiation of monocytes, and blocking CSF1R signaling 
impairs monocyte recruitment without affecting conventional 
DC subsets [Ref. (37) and data not shown].
Treatment with GW2580 induced a marked reduction in 
monocytes and moDCs in the dLNs (Figure  4A) and tumors 
(Figure 4B and data not shown) of MSU + Msmeg-treated mice. 
In addition, administration of GW2580 to prevent monocyte and 
moDC recruitment throughout the duration of MSU + Msmeg 
treatment completely abrogated the antitumor effect (Figure 4C). 
We therefore conclude that moDCs are required for MSU + Msmeg 
tumor therapy.
Monocytes and moDcs Produce 
Proinflammatory Factors and are 
necessary for Proliferation and Tumor 
infiltration of cD8+ T cells
To elucidate the function of moDCs in mediating the antitumor 
activity of MSU + Msmeg, we chose to first investigate whether 
they produce proinflammatory cytokines and iNOS. During 
infections, moDCs are well known to be major producers of TNFα 
and iNOS (13) and can also be a critical source of IL-12 (15, 18). 
In MSU + Msmeg-treated mice, the majority of moDCs in dLN 
were positive for intracellular iNOS and TNFα (Figures 5A,B). 
In addition, about 15% of moDCs costained for both intracellular 
TNFα and IL-12p40 (Figures 5A,B, right panel). Monocytes in 
the same dLN showed a similar pattern of intracellular iNOS, 
TNFα, and IL-12p40 staining, but the proportion of cytokine-
expressing cells was lower compared to moDCs (Figure 5C).
Monocyte-derived DCs have been reported to crossprime 
CD8+ T cells (38, 39) and induce strong Th1 and cytotoxic T 
lymphocyte responses (14, 15, 19). We used B16 tumors express-
ing the model antigen OVA together with adoptive transfer of 
CFSE-labeled naive CD45.1+ OTI T cells to assess priming of 
tumor-specific CD8+ T cells in response to MSU +  Msmeg. 
Consistent with our previous work (9), MSU + Msmeg treat-
ment increased the number of total and divided OTI cells in 
dLN (Figure  6A). Reducing the number of moDCs in dLN 
by treatment with GW2580 inhibited the increase in OTI 
proliferation (Figure 6A), indicating that moDCs were neces-
sary for this response. We then examined the percentage of 
CD8+ T cells and OTI cells in tumors. Again, GW2580 fully 
abrogated the increase in CD8+ T cell and OTI cell infiltration 
into MSU +  Msmeg-treated tumors (Figure  6B). These data 
indicate that moDCs are necessary for the efficient proliferation 
of tumor-specific T cells in the dLN of MSU + Msmeg-treated 
mice, and for their accumulation in the tumor.
moDcs are sufficient for MsU + Msmeg 
antitumor activity
To assess whether moDCs are sufficient for the development of 
antitumor immunity after MSU + Msmeg treatment, we used an 
experimental setup similar to the one outlined in Figure 7A to 
generate mice in which moDCs were the only DC subset present. 
Tumor-bearing CD11c-DTR BM chimeric mice were injected 
with DT to deplete CD11c+ cells throughout the duration of 
MSU + Msmeg treatment. At the same time, mice were adoptively 
transferred with BM monocytes from wild-type (WT) C57BL/6 
mice. As WT monocytes cannot express DTR, they were not 
affected by DT treatment and could differentiate into CD11c+ 
moDC when exposed to the appropriate conditions. In some 
experiments, chimeras were also injected with B16.OVA tumors 
and adoptively transferred with naive OTI CD8+ T cells to assess 
the response of tumor-specific CD8+ T cells.
B16.OVA tumors were analyzed for percentage of total CD8+ 
T cells and antigen-specific OTI cells at the end of MSU + Msmeg 
treatment. Depletion of CD11c+ cells at the time of MSU + Msmeg 
treatment abrogated the increase in CD8+ T cell infiltration into 
the tumor. Transfer of WT monocytes into CD11c-depleted mice 
was sufficient to partially recover CD8+ T cell accumulation 
(Figure  7B, left panel) and completely restored the frequency 
of OTI T cells to levels comparable to those in CD11c-sufficient 
controls (Figure  7B, right panel). Transfer of monocytes also 
restored the antitumor activity of MSU +  Msmeg, resulting in 
reduced tumor size (Figure 7C) and increased survival similar 
to WT controls (Figure 7D). Recovery of the antitumor response 
FigUre 3 | ccl2 is necessary for the recruitment of monocytes to MsU + Msmeg-treated dlns and tumors. (a) Expression of CCR2 on monocytes 
(CD11b+Ly6B+Ly6C+CD11c−), moDCs (CD11c+MHCII+Ly6B+Ly6C+), and other DCs (CD11c+MHCII+Ly6B−Ly6C−) in dLNs of mice treated with MSU + Msmeg once 
45 h earlier. (B) Frequency of CCR2+ monocytes in blood 15 h after MSU + Msmeg treatment. (c,D) Mice bearing palpable B16.OVA tumors were treated with 
anti-CCL2 or control antibody. About 2 h later, mice received 2 million purified CD45.1+ naive monocytes and were treated with MSU + Msmeg. The recruitment of 
transferred (CD45.1+) or host (CD45.2+) monocytes (Ly6B+Ly6C+CD11c−) to LN (c) and tumors (D) was examined 18 h later. Data are pooled from two 
independent experiments each with 3–5 mice/group. All graphs show mean + SEM. Statistical analyses used a Student’s t-test (B) or a Kruskal–Wallis with Dunn’s 
post-test (c,D).
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they produce proinflammatory cytokines and iNOS. During 
infections, moDCs are well known to be major producers of TNFα 
and iNOS (13) and can also be a critical source of IL-12 (15, 18). 
In MSU + Msmeg-treated mice, the majority of moDCs in dLN 
were positive for intracellular iNOS and TNFα (Figures 5A,B). 
In addition, about 15% of moDCs costained for both intracellular 
TNFα and IL-12p40 (Figures 5A,B, right panel). Monocytes in 
the same dLN showed a similar pattern of intracellular iNOS, 
TNFα, and IL-12p40 staining, but the proportion of cytokine-
expressing cells was lower compared to moDCs (Figure 5C).
Monocyte-derived DCs have been reported to crossprime 
CD8+ T cells (38, 39) and induce strong Th1 and cytotoxic T 
lymphocyte responses (14, 15, 19). We used B16 tumors express-
ing the model antigen OVA together with adoptive transfer of 
CFSE-labeled naive CD45.1+ OTI T cells to assess priming of 
tumor-specific CD8+ T cells in response to MSU +  Msmeg. 
Consistent with our previous work (9), MSU + Msmeg treat-
ment increased the number of total and divided OTI cells in 
dLN (Figure  6A). Reducing the number of moDCs in dLN 
by treatment with GW2580 inhibited the increase in OTI 
proliferation (Figure 6A), indicating that moDCs were neces-
sary for this response. We then examined the percentage of 
CD8+ T cells and OTI cells in tumors. Again, GW2580 fully 
abrogated the increase in CD8+ T cell and OTI cell infiltration 
into MSU +  Msmeg-treated tumors (Figure  6B). These data 
indicate that moDCs are necessary for the efficient proliferation 
of tumor-specific T cells in the dLN of MSU + Msmeg-treated 
mice, and for their accumulation in the tumor.
moDcs are sufficient for MsU + Msmeg 
antitumor activity
To assess whether moDCs are sufficient for the development of 
antitumor immunity after MSU + Msmeg treatment, we used an 
experimental setup similar to the one outlined in Figure 7A to 
generate mice in which moDCs were the only DC subset present. 
Tumor-bearing CD11c-DTR BM chimeric mice were injected 
with DT to deplete CD11c+ cells throughout the duration of 
MSU + Msmeg treatment. At the same time, mice were adoptively 
transferred with BM monocytes from wild-type (WT) C57BL/6 
mice. As WT monocytes cannot express DTR, they were not 
affected by DT treatment and could differentiate into CD11c+ 
moDC when exposed to the appropriate conditions. In some 
experiments, chimeras were also injected with B16.OVA tumors 
and adoptively transferred with naive OTI CD8+ T cells to assess 
the response of tumor-specific CD8+ T cells.
B16.OVA tumors were analyzed for percentage of total CD8+ 
T cells and antigen-specific OTI cells at the end of MSU + Msmeg 
treatment. Depletion of CD11c+ cells at the time of MSU + Msmeg 
treatment abrogated the increase in CD8+ T cell infiltration into 
the tumor. Transfer of WT monocytes into CD11c-depleted mice 
was sufficient to partially recover CD8+ T cell accumulation 
(Figure  7B, left panel) and completely restored the frequency 
of OTI T cells to levels comparable to those in CD11c-sufficient 
controls (Figure  7B, right panel). Transfer of monocytes also 
restored the antitumor activity of MSU +  Msmeg, resulting in 
reduced tumor size (Figure 7C) and increased survival similar 
to WT controls (Figure 7D). Recovery of the antitumor response 
FigUre 3 | ccl2 is necessary for the recruitment of monocytes to MsU + Msmeg-treated dlns and tumors. (a) Expression of CCR2 on monocytes 
(CD11b+Ly6B+Ly6C+CD11c−), moDCs (CD11c+MHCII+Ly6B+Ly6C+), and other DCs (CD11c+MHCII+Ly6B−Ly6C−) in dLNs of mice treated with MSU + Msmeg once 
45 h earlier. (B) Frequency of CCR2+ monocytes in blood 15 h after MSU + Msmeg treatment. (c,D) Mice bearing palpable B16.OVA tumors were treated with 
anti-CCL2 or control antibody. About 2 h later, mice received 2 million purified CD45.1+ naive monocytes and were treated with MSU + Msmeg. The recruitment of 
transferred (CD45.1+) or host (CD45.2+) monocytes (Ly6B+Ly6C+CD11c−) to LN (c) and tumors (D) was examined 18 h later. Data are pooled from two 
independent experiments each with 3–5 mice/group. All graphs show mean + SEM. Statistical analyses used a Student’s t-test (B) or a Kruskal–Wallis with Dunn’s 
post-test (c,D).
FigUre 4 | Treatment with the csF1-signaling inhibitor gW2580 impairs monocyte and moDcs recruitment and abrogates the antitumor activity of 
MsU + Msmeg. Mice bearing B16.OVA tumors were treated with MSU + Msmeg, and at the same time they received daily oral doses of GW2580 or vehicle 
control. LN and tumors were analyzed 2 days after the last MSU + Msmeg treatment. (a) Numbers of monocytes (CD11b+Ly6B+Ly6C+CD64+CD11c−) and moDCs 
(CD11b+Ly6B+Ly6C+CD11c+MHCII+) in dLN. (B) Frequencies of monocytes (CD45+CD11b+Ly6ChighLy6G−CD11c−), total DCs (CD45+CD11c+MHCII+), and moDCs 
(CD45+CD11c+MHCII+CD11b+Ly6C+Ly6B+) in tumors. (c) Tumor sizes on day 13. All data are pooled from two independent experiments each with 5 mice/group. 
Graphs show mean + SEM. Statistical analyses used ANOVA with Tukey’s post-test (a) or a Kruskal–Wallis with Dunn’s post-test (B,c).
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did not require transfer of OTI T cells and occurred regardless of 
challenge with B16 or B16.OVA tumors, or OTI transfer. These 
results indicate that, in a situation where other CD11c+ cells are 
depleted, moDCs are sufficient for induction of tumor-specific 
CD8+ T cell responses and successful tumor immunity in response 
to MSU + Msmeg.
DiscUssiOn
In this study, we investigated the role of moDCs in the anti-
tumor immune response elicited by local treatment with 
MSU + Msmeg. We show that DCs are necessary for the activity 
of MSU + Msmeg, as depletion of CD11c+ cells completely abro-
gated the antitumor effect. Interestingly, blockade of CSF1R to 
selectively deplete moDCs without affecting other DC subsets 
also abrogated the effect of immunotherapy. In a reciprocal 
fashion, adoptive transfer of monocytes into mice depleted 
of CD11c+ cells was sufficient to restore antitumor activity. 
MoDCs originated from circulating monocytes in response to 
MSU +  Msmeg treatment, expressed iNOS, TNFα, and IL-12 
and were necessary for the priming of tumor-specific CD8+ 
T cells. In addition, moDCs were necessary and sufficient for 
the accumulation of tumor-specific CD8+ T cells in tumors. 
Together, these data show that moDCs play an essential role 
during immunotherapy with MSU + Msmeg.
The experiments in this paper investigated the role of moDCs 
using a model of B16 melanoma and immunotherapy with 
MSU + Msmeg. Our previous work compared several different 
treatments with immunostimulatory agents, including LPS, 
polyI:C (9), and CpG immunostimulatory oligonucleotides 
FigUre 5 | Monocytes and moDcs in dln express proinflammatory mediators after MsU + Msmeg treatment. Mice were treated with a single dose of 
MSU + Msmeg s.c., and 19 h later dLNs were collected and analyzed by intracellular staining for the indicated markers. Staining controls included an isotype control 
(isotype) and stained samples that were not treated with GolgiStop/Brefeldin A (no block). (a) Representative flow plots and (B) frequencies of iNOS-, IL-12-, and 
TNFα-expressing moDCs (CD11c+MHCII+CD11b+Ly6B+Ly6C+). (c) Frequencies of monocytes (CD11b+Ly6B+Ly6C+CD11c−) expressing proinflammatory molecules. 
Data are from one of two independent experiments, each with 3–5 mice/group that gave similar results. Graphs show means + SEM. Statistical analyses used a 
Student’s t-test.
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FigUre 6 | Monocyte-derived Dcs are necessary for the proliferation of tumor-specific cD8+ T cells in dln and their infiltration into tumors. Mice 
bearing B16.OVA tumors were treated with MSU + Msmeg, and at the same time they were given daily oral doses of GW2580 or vehicle. LN and tumors were 
analyzed 2 days after the last MSU + Msmeg treatment. (a) Numbers of total and divided OTI T cells (CD45.1+CD8α+ lymphocytes) in tumor dLN, as assessed by 
CFSE dilution. (B) Total CD8+ and OTI T cells (CD45+CD8α+ and CD45+CD8α+CD45.1+, respectively) expressed as frequencies of total live cells in tumors. Data are 
pooled from two independent experiments, each with 5 mice/group. All graphs show mean + SEM. Statistical analyses were by one-way ANOVA with Tukey’s 
post-test (a) and Kruskal–Wallis test with Dunn’s post-test (B).
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(unpublished data), to show that antitumor activity correlated 
with increased numbers of moDCs in the tumor dLN. In addi-
tion, treatments that were effective on B16 melanoma were also 
effective on EL4 thymomas (11) and 4T1 mammary carcinomas 
(9), suggesting that the requirement for moDCs in antitumor 
immune responses extends to other forms of immunotherapy 
besides MSU + Msmeg, and to multiple tumor models.
Our finding that CCR2+Ly6Chigh monocytes were recruited 
to MSU + Msmeg dLNs and tumors is consistent with literature 
showing that these monocytes are preferentially attracted to 
sites of inflammation (35). Accordingly, the strong reduction 
in monocyte recruitment after treatment with CCL2-blocking 
antibodies suggests that CCR2–CCL2 interactions are largely 
responsible for the attraction of monocytes to the site of 
MSU  +  Msmeg treatment (23, 30, 36). While there is clear 
evidence that monocytes can differentiate into moDCs during 
inflammation (13, 14, 35) surprisingly little is known about the 
signals that govern this process. In line with our findings, CSF1 
is the major lineage regulator of mononuclear phagocytes in the 
BM and thus is required for the development of monocytes and 
subsequently moDCs (40). The upregulation of MHCII and pro-
duction of IL-12p40 by moDCs instead were shown to depend 
on natural killer (NK) cell-derived IFNγ in a study of Toxoplasma 
gondii infection (18). In our model, depletion of NK1.1+ cells 
did not reduce the number of MHCII+ moDCs in dLN after 
MSU + Msmeg treatment (data not shown), suggesting that NK 
cells were not vital for moDC differentiation. However, NK cells 
may be important for the function of moDCs, a possibility that 
was not examined in our experiments.
In our study, a significant proportion of moDCs expressed 
IL-12p40. The critical role of IL-12 for the induction of cytotoxic 
T lymphocytes and for antitumor immunity is well established. 
In addition, moDCs produced TNFα and iNOS. This activity was 
previously used as a defining feature of monocyte-derived “TIP” 
DCs (13). Mounting evidence suggests that TNFα is important 
for antitumor immunity, as shown by experiments where tumor 
immunotherapy with polyI:C required TNFα for treatment suc-
cess (41). Furthermore, a recent study showed that the combined 
action of TNFα and IFNγ is necessary for the control of a range 
of murine and human tumors by driving cancer cells into senes-
cence (20).
In contrast to IL-12 and TNFα, the role of NO/iNOS in tumors 
is more controversial. A number of studies have shown that 
macrophage- or MDSC-derived NO can suppress antitumor T 
cell responses in vitro [reviewed in Ref, (42)]. However, others 
report that NO is required for direct tumoricidal activity of mac-
rophages in vitro (43, 44). In vivo data are unfortunately limited 
and suggest that the effects of NO in  vivo may not always be 
accurately reflected in ex vivo suppression experiments (45). This 
notion is further supported by the finding that in a spontaneous 
melanoma model ROS-producing monocytic effector cells have 
direct antitumor activity that is independent of T cells (27). It is 
possible that in our model monocytes and moDCs exerted some 
direct antitumor activity via iNOS and TNFα, as these factors 
FigUre 7 | Monocyte-derived Dcs are sufficient for the recruitment of cD8+ T cells to tumors and the activation of antitumor immunity. 
(a) Schematic representation of experimental design. C57BL/6 WT (C57WT) or CD11c-DTR BM chimeras were injected with B16 melanoma tumors, treated every 
second day for four times with MSU + Msmeg or PBS, and at the same time depleted of CD11c+ cells by DT treatment as indicated. Some of these mice were also 
injected with WT BM monocytes to obtain mice where moDC populations could only originate from the injected monocytes. (B) Mice were treated as in (a), except 
that tumors were B16.OVA, and all mice also received naive OTI cells given at the time of the second dose of immunotherapy. Graphs show the percentage of CD8+ 
T cells (CD45+CD4−CD8+) and OTI cells (CD45+CD4−CD8+CD45.1+) among total live cells in tumors 2 days after the fourth MSU + Msmeg treatment. Data are 
pooled from two independent experiments each with 5 mice/group. Graphs show mean + SEM. Statistical analysis used a Kruskal–Wallis test with Dunn’s 
post-test. (c) Mean tumor sizes + SEM on day 21 after tumor challenge. Data are pooled from three independent experiments each with 5 mice/group. Statistical 
analysis was by ANOVA with Tukey’s post-test. (D) Survival data, pooled from two independent experiments each with 5 mice/group. Statistical significance was 
evaluated using a log-rank test and Bonferroni’s correction.
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were expressed by monocytes and moDC in the dLN and also in 
the tumor (data not shown). However, MSU + Msmeg therapy 
of B16 melanoma was CD8+ T cell dependent (9), and CD8+ T 
cell proliferation was strongly diminished when moDCs were 
blocked. Therefore, one major role of moDCs was in support-
ing the priming of CD8+ T cells, although we cannot rule out 
additional direct antitumor functions.
We have previously shown that in the steady state CD11c+ 
DCs are necessary for crosspresentation to tumor-specific CD8+ 
T cells in dLN, as CD8+ T cell proliferation was abrogated in mice 
depleted of CD11c+ cells (9). The experiments presented here 
reveal that, during immunotherapy, blockade of CSF1R-dependent 
monocytes and moDCs reduced CD8+ T cell proliferation in dLN 
to a level similar to that observed in the steady state. Therefore, 
promoting the activation of adaptive antitumor immunity is likely 
to be a key function of moDCs during MSU + Msmeg therapy. 
We also observed a striking impact of moDCs on the infiltration 
of CD8+ T cells into tumors. This may merely reflect increased 
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priming in dLN, or it may be due to increased recruitment of 
effector cells driven by monocytes and/or moDCs. It is also pos-
sible that moDCs may prime CD8+ T cells directly at the tumor 
site as suggested by Ma et al. (29), but the profound differences 
we see in dLN suggest that functionally relevant responses are 
occurring at this site during MSU + Msmeg therapy.
Transferred monocytes were sufficient to restore infiltration 
of proliferated CD8+ T cells into the tumors of CD11c-depleted 
mice. This finding suggests that moDCs can crossprime CD8+ 
T cells, either directly, or perhaps in cooperation with other 
cell subsets in CD11c-depleted mice. CD8+ or CD103+ DCs 
are known to be particularly effective at crosspriming, and two 
recent papers report that the presence of CD103+ DCs in tumors 
correlates with spontaneous tumor rejection (4) and response to 
treatment with paclitaxel in combination with CSF1 blockade 
(21). While those papers highlight the function of CD103+ DCs, 
they do not rule out a role for other DC subsets. Under physi-
ological conditions, different DC subsets, such as CD103+ DCs 
and moDCs, may collaborate to induce optimal antitumor CD8+ 
T cell responses. The relative importance of both subsets may 
depend on the type of tumor, as different tumors vary in the ratio 
of CD103+ and CD11b+ DCs that infiltrate them (4), and would 
also be substantially affected by the inflammatory environment 
(9, 29). Furthermore, therapies may also preferentially activate 
CD103+ DCs or moDCs depending on the expression of recep-
tors for damage- and pathogen-associated molecular patterns in 
these cell populations. A systematic study comparing the effect 
of different treatments on several DC subsets and in a range of 
tumors would be needed to fully address this issue.
CSF1-dependent monocytes and monocyte-derived cells 
including tumor-associated macrophages, MDSCs, and moDCs 
express a vast range of receptors to sense the local environment 
and are highly plastic in their response to various stimuli. This may 
explain why several studies show improved antitumor responses 
after CSF1/CSF1R blockade when combined with radiotherapy, 
chemotherapy, or antiangiogenic therapy (21, 37, 46–48) but no 
difference with CSF1 inhibition alone (46, 48, 49), or even suggest 
that monocytic cells may be important for antitumor responses 
(27, 29, 50). Here, we show that CSF1R inhibition can have a 
detrimental effect on tumor therapy, not only by depleting mac-
rophage effector cells (51) but also by impairing the activation of 
tumor-specific T cells during immunotherapy. In line with the 
variable results of CSF1/CSF1R blockade, CSF1 gene signatures 
themselves were found to be either associated with poor survival 
or with improved survival, depending on the specific subtype of 
breast cancer (52). In a similar manner, macrophages can elimi-
nate tumors through secretion of cytotoxic factors (44, 45) and be 
associated with increased survival in patients (53), but more often 
they promote tumor growth (21, 54). Even tumor-infiltrating 
MDSCs, generally thought to be highly immune suppressive, 
have been shown to exhibit plasticity and acquire the ability to 
crossprime antitumor CD8+ T cells in response to IL-12 (55).
CSF1R inhibitors are currently being tested in clinical trials 
of cancer therapy in patients1. However, our data indicate that 
in some cases CSF1 may actually be critical for the initiation 
of antitumor responses. This highlights the need for caution in 
combining CSF1R blockade with other therapies. The role of the 
immune system in mediating antitumor responses not only after 
immunotherapy but also in certain chemotherapies and radio-
therapy is increasingly recognized. Therefore, it is important to 
fully delineate the role of monocytic cell populations in different 
types of tumors and treatments before carefully considering the 
situations in which a combination with CSF1 blockade may be 
beneficial. Our results indicate that, for the purpose of tumor 
therapy, blocking or eliminating monocytic cells will likely be less 
productive than appropriately activating them to harness their 
properties and promote powerful antitumor immune responses.
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